Bibliography
- Alavi S, Arzanian MT, Abbasian MR, Ashena Z. Tumor lysis syndrome in children with non-Hodgkin lymphoma. Pediatr Hematol Oncol 2006;23(1):65-70
- Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127(1):3-11
- Del Toro G, Morris E, Cairo MS. Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approaches. Clin Adv Hematol Oncol 2005;3(1):54-61
- Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993;94(2):133-9
- Hochberg J, Cairo MS. Tumor lysis syndrome: current perspective. Haematologica 2008;93(1):9-13
- Jeha S. Tumor lysis syndrome. Semin Hematol 2001;38(4 Suppl 10):4-8
- Yarpuzlu AA. A review of clinical and laboratory findings and treatment of tumor lysis syndrome. Clin Chim Acta 2003;333(1):13-8
- Howard SC, Pui CH. Pitfalls in predicting tumor lysis syndrome. Leuk Lymphoma 2006;47(5):782-5
- Bessmertny O, Robitaille LM, Cairo MS. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome. Curr Pharm Des 2005;11(32):4177-85
- Klinenberg JR, Goldfinger SE, Seegmiller JE. The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Ann Intern Med 1965;62:639-47
- Yeldandi AV, Yeldandi V, Kumar S, et al. Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. Gene 1991;109(2):281-4
- Legoux R, Delpech B, Dumont X, et al. Cloning and expression in escherichia coli of the gene encoding aspergillus flavus urate oxidase. J Biol Chem 1992;267(12):8565-70
- Masera G, Jankovic M, Zurlo MG, et al. Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J Pediatr 1982;100(1):152-5
- Pui CH, Relling MV, Lascombes F, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 1997;11(11):1813-6
- Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001;19(3):697-704
- Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003;21(23):4402-6
- Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001;97(10):2998-3003
- Pui CH, Jeha S, Irwin D, Camitta B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001;15(10):1505-9
- Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003;98(5):1048-54
- Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005;19(1):34-8
- Navolanic PM, Pui CH, Larson RA, et al. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia 2003;(3):499-514
- Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007;109(7):2736-43
- Candrilli S, Bell T, Irish W, et al. A comparison of inpatient length of stay and costs among patients with hematologic malignancies (excluding hodgkin disease) associated with and without acute renal failure. Clin Lymphoma Myeloma 2008;8(1):44-51
- Annemans L, Moeremans K, Lamotte M, et al. Incidence, medical resource utilization and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma 2003;44(1):77-83
- Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008;26(16):2767-78